First do no harm
Author:
- Mark GreenerMGMark Greener
Open Access
- 8 February 2008
- journal article
- Published by Springer Nature in EMBO Reports
- Vol. 9 (3) , 221-224
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Lessons From the Avandia ControversyDiabetes Care, 2007
- Adverse Effects of Inhaled Corticosteroids in Funded and Nonfunded StudiesArchives of internal medicine (1960), 2007
- Serious Adverse Drug Events Reported to the Food and Drug Administration, 1998-2005Archives of internal medicine (1960), 2007
- Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular CausesNew England Journal of Medicine, 2007
- Case reports of suspected adverse drug reactions—systematic literature survey of follow-upBMJ, 2006
- Drug safety on trialEMBO Reports, 2005
- Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trialThe Lancet, 2004
- Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trialThe Lancet, 2004
- Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid ArthritisNew England Journal of Medicine, 2000